Kimberly Kinnebrew, PA
Medical · Anchorage, AKNPI 1437186889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novartis at 25.4% of the total. Among medical clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$898
- AbbVie$738
- Johnson & Johnson$556
- Lilly USA, LLC$237
- UCB, Inc.$184
- LEO Pharma Inc.$133
- plus $791 from 15 others
What the payments were for
- Food & beverage$3,34394%
- Education$1956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 62 | $898 |
| AbbVie | 54 | $738 |
| Johnson & Johnson | 30 | $556 |
| Lilly USA, LLC | 13 | $237 |
| UCB, Inc. | 9 | $184 |
| LEO Pharma Inc. | 6 | $133 |
| E.r. Squibb & Sons, L.L.C. | 5 | $127 |
| Sanofi | 5 | $109 |
| Arcutis Biotherapeutics, Inc. | 5 | $95 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $86 |
| Amgen | 5 | $77 |
| Incyte Corporation | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Dermira, Inc. | 2 | $35 |
| VYNE Pharmaceuticals Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Organon | 1 | $21 |
| Sandoz | 1 | $19 |
| Organogenesis Inc. | 1 | $19 |
| Pfizer | 1 | $13 |
| Janssen Scientific Affairs, LLC | 1 | $7 |
How this compares
$3,538 in reported general payments places this provider in the 90th percentile of 140 medical providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pimecrolimus | 14 | $2,730 |
| Clobetasol Propionate | 35 | $1,982 |
| Tacrolimus | 21 | $1,398 |
| Triamcinolone Acetonide | 82 | $937 |
| Doxycycline Monohydrate | 26 | $580 |
| Cephalexin | 19 | $422 |
| Metronidazole | 13 | $288 |
Paid to pharmacies, not to this prescriber.
Other medical in Anchorage
- Christina FroilandAnchorage$22K
- Adrian GianiAnchorage$6K
- Ivy WeaklandAnchorage$4K
- Hope McGrattyAnchorage$4K
- Jaime ZipsirAnchorage$4K
- Jeffrey StubblefieldAnchorage$4K
- Jennifer FayetteAnchorage$3K
- Eric SuojaAnchorage$3K
- Stephanie WettinAnchorage$3K
- Hailey LankfordAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.